Dow Falls 150 Points; Oracle Posts Downbeat Results
Dow Falls 150 Points; Oracle Posts Downbeat Results
In trading on Tuesday, utilities shares fell by 1.1%.U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday.
今天上午美国股市涨跌互现，道琼斯指数周二下跌约150点。
Following the market opening Tuesday, the Dow traded down 0.36% to 44,242.81 while the NASDAQ rose 0.43% to 19,820.91. The S&P 500 also fell, dropping, 0.01% to 6,052.43.
周二开盘后，道琼斯指数下跌0.36％，至44,242.81点，而纳斯达克指数上涨0.43％，至19,820.91点。标准普尔500指数也下跌了0.01％，至6,052.43点。
Leading and Lagging Sectors
Communication services shares jumped by 2.3% on Tuesday.
领先和落后的行业
周二，通信服务股上涨了2.3％。
In trading on Tuesday, utilities shares fell by 1.1%.
在周二的交易中，公用事业股下跌了1.1％。
Top Headline
热门标题
Oracle Corporation (NYSE:ORCL) posted weaker-than-expected earnings and sales results for its second quarter on Monday.
甲骨文公司（纽约证券交易所代码：ORCL）周一公布的第二季度收益和销售业绩均低于预期。
The company reported second-quarter revenue of $14.06 billion, up 9% year-over-year. The revenue total missed a Street consensus estimate of $14.11 billion.
该公司报告第二季度收入为140.6亿美元，同比增长9％。总收入未达到华尔街共识估计的141.1亿美元。
Equities Trading UP
股票交易上涨
- Chimerix, Inc. (NASDAQ:CMRX) shares shot up 172% to $2.36 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.
- Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) got a boost, surging 112% to $2.6400 after the company announced the FDA has approved its supplemental new drug application for acetadote.
- uniQure N.V. (NASDAQ:QURE) shares were also up, gaining 104% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.
- Chimerix, Inc.（纳斯达克股票代码：CMRX）股价飙升了172％，至2.36美元，此前该公司宣布将向美国食品药品管理局提交用于复发性H3 K2700万突变弥漫性神经胶质瘤患者的多达维酮，以加速获得美国食品药品管理局的批准。
- 坎伯兰制药公司（纳斯达克股票代码：CPIX）的股价上涨，在该公司宣布美国食品药品管理局已批准其醋酸盐补充新药申请后，该公司股价飙升了112％，至2.6400美元。
- UniQure N.V.（纳斯达克股票代码：QURE）股价也上涨了104％，至15.00美元，此前该公司宣布与美国食品药品管理局就AMT-130加速路径的关键要素达成协议。
Equities Trading DOWN
股票交易下跌
- CervoMed Inc. (NASDAQ:CRVO) shares dropped 75% to $2.54 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.
- Shares of Biora Therapeutics, Inc. (NASDAQ:BIOR) were down 44% to $0.7499.
- MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) was down, falling 41% to $1.65. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.
- CervoMed Inc.（纳斯达克股票代码：CRVO）股价下跌75％，至2.54美元，此前该公司宣布其Neflamapimod的第20期试验未能达到其治疗痴呆症的关键终点。
- Biora Therapeutics, Inc.（纳斯达克股票代码：BIOR）的股价下跌44％，至0.7499美元。
- MediRom Healthcare Technologies Inc.（纳斯达克股票代码：MRM）下跌41％，至1.65美元。Medirom Healthcare将其500万美元的286万股美国存托股票的公开发行定价为每股ADS1.75美元。
Commodities
In commodity news, oil traded up 0.1% to $68.40 while gold traded up 1% at $2,712.20.
大宗商品
在大宗商品新闻方面，石油价格上涨0.1％，至68.40美元，而黄金上涨1％，至2712.20美元。
Silver traded up 0.4% to $32.750 on Tuesday, while copper fell 0.6% to $4.2500.
周二，白银上涨0.4％，至32.750美元，而铜价下跌0.6％，至4.2500美元。
Euro zone
欧元区
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.2%, Germany's DAX rose 0.2% and France's CAC 40 fell 0.6%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.6%.
今天欧洲股市大多走低。欧元区斯托克600指数下跌0.2％，德国DAX指数上涨0.2％，法国CAC 40指数下跌0.6％。西班牙的IBEX 35指数下跌0.1％，而伦敦富时100指数下跌0.6％。
Asia Pacific Markets
亚太市场
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
周一亚洲市场收盘涨跌互现，日本日经225指数上涨0.18％，香港恒生指数上涨2.76％，中国上证综合指数下跌0.05％，印度BSE Sensex下跌0.25％。
Economics
经济学
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.
美国非农商业部门的劳动生产率在第三季度增长了2.2％，与初步数据一致。
Now Read This:
现在阅读这篇文章：
- Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
- 亚马逊将上涨约15％？以下是周二分析师的十大预测
